Idience is a clinical-stage biopharmaceutical company, established in 2019 as a subsidiary company of Ildong Holdings, focused on oncology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
Idience’s leading therapeutic candidate is IDX-1197, a potent PARP inhibitor, which has demonstrated superior outcome potential to currently commercially available PARP inhibitors and possibilities for new treatment options with additional indications in its non-clinical studies. IDX-1197 is currently under Phase 1a and Phase 1b/2a clinical studies targeting multiple solid tumors.
If you have questions, please contact firstname.lastname@example.org